( efficacious and acton select targets....)Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA,Health

efficacious and act on select targets. Arisaph has successfully applied its specificity profiling and retro-inversal chiral chemistry technology platforms to synthesize promising candidate drugs for seven targets, including ARI-2243, a lead candidate for DPP-4 inhibition to treat type II diabetes, currently undergoing non-clinical toxicology evaluation, and ARI-1778 or reverse D-4F, an orally active mimetic peptide, being developed in collaboration with Abbott Laboratories to treat atherosclerosis. Through a licensing agreement with Tufts University the Company has exclusive worldwide rights to several important issued patents in the diabetes area and several pending patents that have utility for the treatment of cancer and cardiovascular disease.

About DPP-4:

DPP-4 or dipeptidylpeptidase type 4 is a naturally occurring, proteolytic enzyme that rapidly degrades the incretin hormones, gastric inhibitory polypeptide (GIP) and glucagon-like protein (GLP-1). GLP-1 has a favorable anti-diabetic role because it stimulates glucose dependent insulin secretion from the pancreas, slows gastric emptying and decreases glucagon secretion. Inhibitors to DPP-4 improve glycemic control in patients with type II diabetes by increasing the half-life of native GLP-1. DPP-4 is a validated target for the treatment of type II diabetes and inhibitors of DPP-4 have been shown to lower post-prandial glucose and HbA1c levels. Diabetes is a major healthcare problem throughout the world with the prevalence of the disease projected to double to 300 million cases worldwide by the year 2025 according to the World Health Organization.

Certain statements in this press release, including statements regarding the Company's research and development effort, the Company's expectation to complete IND enabling studies and to initiate human clinical studies ,the Company's ability to finance its development programs into initial human clinical testing, and the Company's ability to succe
'"/>

Page: 1 2 3 4
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting